Clinical Trial Update: Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating naltrexone for opioid dependence in HIV+ criminal justice populations has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug Dependence
• HIV Infection
• Opioid Dependence

Drugs mentioned

• Naltrexone (Naltrexone)

Snippet

Sponsor: Yale University | Conditions: HIV, AIDS | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-07-17